Orlistat as a clomiphene citrate adjuvant in overweight and obese patients with polycystic ovary syndrome.

Orlistat as a clomiphene citrate adjuvant in overweight and obese patients with polycystic ovary syndrome. - Orlistat as a clomiphene citrate adjuvant in overweight and obese patients with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029071

Enrollment

Registered

2018-05-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recruiting

Interventions

receive clomiphene citrate for 6 months 5 days at the start of menstruation plus orlista 3 times/day for 6 months or stopped when patient get pregnant receive clomiphene citrate only for 5 days / mon

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: PCO patients diagnosed by revised Rotterdam's criteria 2003 age 18-35years BMI >25 and <35 no recent history of drug intake or deitary modifications

Exclusion criteria

Exclusion criteria: Male factor all other causes of infertility untreated hypothyriodism hyperprolactinemia renal or hepatic impairment malabsorption syndrome

Design outcomes

Primary

Measure	Time frame
clinical pregnancy rate	—

Secondary

Measure	Time frame
weight reduction	—

Countries

Africa

Contacts

Public ContactAyman Dawood

Tanta university Eman Heikal

ayman.dawood@med.tanta.edu.eg+201020972067

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026